Product Information
COLESEVELAM 625 MG TABLET is a generic product labeled by Ascend Laboratories, LLC, priced at $0.2617 per EA under NDC 67877050651. Its NADAC has been published 405 times since Jan 2, 2019.
FDA first approved this application on Oct 5, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
625 mg/1
Manufacturer
Ascend Laboratories, LLCNDC
67877050651
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
COLESEVELAM HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209038FDA Approved
10/5/2018
TE Code
AB
On Market Since
10/6/2018
Pharmacological Classes
Price Statistics
The NADAC for COLESEVELAM 625 MG TABLET has been published 405 times since Jan 2, 2019, and over the history we have for it it has declined 86.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2617 per EA |
|---|---|
| All-time high | $1.8868 (Jan 16, 2019) |
| All-time low | $0.1763 (Jul 17, 2024) |
| 52-week high | $0.2904 |
| 52-week low | $0.2608 |
| Median price | $0.3999 |
| Average price | $0.4896 |
| Largest weekly change | +56.2% (May 17, 2023) |
| Weeks tracked | 405 |
| Tracking since | Jan 2, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Colesevelam HCL market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Ascend Laboratories, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Colesevelam HCL market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bile Acid Sequestrant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of COLESEVELAM 625 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for COLESEVELAM 625 MG TABLET, manufactured by Ascend Laboratories, LLC, is $0.2617 per EA (NDC 67877050651), effective Sep 30, 2026.
How has the price of COLESEVELAM 625 MG TABLET changed over time?
Over the history we have for it, the NADAC for COLESEVELAM 625 MG TABLET has declined 86.1%. It has been tracked across 405 weekly CMS publications since Jan 2, 2019.
What are the highest and lowest recorded NADAC prices for COLESEVELAM 625 MG TABLET?
Since Jan 2, 2019, the NADAC for COLESEVELAM 625 MG TABLET has ranged from a low of $0.1763 (Jul 17, 2024) to a high of $1.8868 (Jan 16, 2019), with a median of $0.3999 per EA.
Are there cheaper alternatives to COLESEVELAM 625 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of COLESEVELAM 625 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures COLESEVELAM 625 MG TABLET?
COLESEVELAM 625 MG TABLET (NDC 67877050651) is labeled by Ascend Laboratories, LLC, and CMS classifies it as a generic product.